Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug

摘要

The present invention provides methods for the treatment of lung cancer patients, especially NSCLC with SCC or PLC using a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab. In addition, the present invention provides methods for identification or selection of lung cancer patients for the treatment with a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab based on histological determinations.